We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Sekisui Diagnostics UK Ltd.

Download Mobile App




Spectranetics Completes Acquisition of AngioScore

By HospiMedica International staff writers
Posted on 13 Jul 2014
Print article
Spectranetics (Colorado Springs, CO, USA) has completed the acquisition of AngioScore (Fremont, CA, USA), a leading developer, manufacturer, and marketer of cardiovascular specialty balloons.

The transaction, for USD 230 million in cash and contingent commercial and regulatory milestone payments, will combine differentiated, complementary product lines. The acquisition will diversify Spectranetics’ current product portfolio, which includes a range of ablation laser catheters, support catheters to facilitate crossing of peripheral and coronary arterial blockages, and retrograde access and guidewire retrieval devices. The company also markets a lead management product line that includes excimer laser sheaths, dilator sheaths, mechanical sheaths, and accessories for the removal of pacemaker and defibrillator cardiac leads.

The acquisition will expand physicians’ options for treating critical limb ischemia (CLI), in‐stent restenosis (ISR), calcified lesions, and chronic total occlusions (CTO). Strategically, the combined company will expand Spectranetics’ addressable markets, broaden the product pipeline (including the addition of a proprietary drug‐coated scoring balloon platform), enhance and leverage Spectranetics’ strong sales and marketing capabilities, and drive significant operating efficiencies and savings.

“We are very excited to complete this important transaction. AngioScore meets our criteria with an exceptional strategic fit, leverageable call points, differentiated technology and clear operating efficiencies,” said Scott Drake, President and CEO of Spectranetics. “With AngioScore now a part of our company, we have a meaningfully expanded market opportunity and a compelling product portfolio.”

“Simply put, we are ‘better together.’ We believe that this combination provides an opportunity to build a remarkable future while delivering life‐impacting technologies to physicians and patients,” said Thomas R. Trotter, President and CEO of AngioScore. “In Spectranetics, we find a like‐minded partner that shares our values, our commitment to improving patients’ lives, and equally high standards for operational excellence and quality.”

Related Links:

Spectranetics
AngioScore


Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Silver Member
Wireless Mobile ECG Recorder
NR-1207-3/NR-1207-E
New
X-Ray QA Meter
Piranha CT

Print article

Channels

Surgical Techniques

view channel
Image: LUMISIGHT and Lumicell DVS offer 84% diagnostic accuracy in detecting residual cancer (Photo courtesy of Lumicell)

Cutting-Edge Imaging Platform Detects Residual Breast Cancer Missed During Lumpectomy Surgery

Breast cancer is becoming increasingly common, with statistics indicating that 1 in 8 women will develop the disease in their lifetime. Lumpectomy remains the predominant surgical intervention for treating... Read more

Patient Care

view channel
Image: The newly-launched solution can transform operating room scheduling and boost utilization rates (Photo courtesy of Fujitsu)

Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization

An innovative solution has the capability to transform surgical capacity utilization by targeting the root cause of surgical block time inefficiencies. Fujitsu Limited’s (Tokyo, Japan) Surgical Capacity... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The Quantra Hemostasis System has received US FDA special 510(k) clearance for use with its Quantra QStat Cartridge (Photo courtesy of HemoSonics)

Critical Bleeding Management System to Help Hospitals Further Standardize Viscoelastic Testing

Surgical procedures are often accompanied by significant blood loss and the subsequent high likelihood of the need for allogeneic blood transfusions. These transfusions, while critical, are linked to various... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.